SEITO Biologics
Biotechnology Research • 
Stadtkreis 1 Altstadt, Zurich, Switzerland • 1-10 Employees
Company overview
| Headquarters | Stadtkreis 1 Altstadt, Zurich, Switzerland |
| Website | |
| NAICS | 541714 |
| Keywords | Immunotherapy, Tolerance, Autoimmunity, Cytokines, Regulatory T Cells |
| Employees | 1-10 |
| Socials |
Key Contact at SEITO Biologics
Ufuk Karakus
CSO & Co-Founder
SEITO Biologics Email Formats
SEITO Biologics uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@seitobio.ch), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@seitobio.ch | 100% |
About SEITO Biologics
SEITO is dedicated to developing innovative immunotherapies for immune-mediated diseases, including autoimmune disorders, chronic inflammation, and transplant rejection. These conditions, which are both serious and lifelong, impact approximately 4% of the population in developed countries. Our approach focuses on engineering regulatory T (Treg) cell engagers (TREX) to precisely and safely activate Treg cells, helping to restore immune balance and prevent harmful self-targeted immune responses.
SEITO Biologics revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | $3,400,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
SEITO Biologics has 1 employees across 1 departments.
Departments
Number of employees
United States
France
Australia
BelgiumFrequently asked questions
4.8
40,000 users
